[HTML][HTML] HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial
EA Perez, MM Reinholz, DW Hillman… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
EA Perez, MM Reinholz, DW Hillman, KS Tenner, MJ Schroeder, NE Davidson, S Martino…
Journal of clinical oncology, 2010•ncbi.nlm.nih.govPurpose We examined associations between tumor characteristics (human epidermal
growth factor receptor 2 [HER2] protein expression, HER2 gene and chromosome 17 copy
number, hormone receptor status) and disease-free survival (DFS) of patients in the N9831
adjuvant trastuzumab trial.
growth factor receptor 2 [HER2] protein expression, HER2 gene and chromosome 17 copy
number, hormone receptor status) and disease-free survival (DFS) of patients in the N9831
adjuvant trastuzumab trial.
Abstract
Purpose
We examined associations between tumor characteristics (human epidermal growth factor receptor 2 [HER2] protein expression, HER2 gene and chromosome 17 copy number, hormone receptor status) and disease-free survival (DFS) of patients in the N9831 adjuvant trastuzumab trial.
ncbi.nlm.nih.gov
